Summit Creek Advisors LLC bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 49,174 shares of the medical instruments supplier’s stock, valued at approximately $4,719,000.
Several other large investors have also modified their holdings of LMAT. BlackRock Inc. purchased a new stake in shares of LeMaitre Vascular in the 2nd quarter worth approximately $314,075,000. Vanguard Group Inc. increased its holdings in LeMaitre Vascular by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after buying an additional 21,946 shares during the period. Conestoga Capital Advisors LLC raised its stake in LeMaitre Vascular by 3.6% in the first quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock worth $161,224,000 after buying an additional 51,825 shares in the last quarter. First Trust Advisors LP raised its stake in LeMaitre Vascular by 6.2% in the first quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock worth $108,959,000 after buying an additional 57,931 shares in the last quarter. Finally, State Street Corp lifted its holdings in LeMaitre Vascular by 0.8% during the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after buying an additional 6,130 shares during the period. Institutional investors own 84.64% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts have issued reports on LMAT shares. Barrington Research cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Citizens Jmp boosted their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $110.60.
LeMaitre Vascular Price Performance
Shares of LMAT opened at $81.52 on Wednesday. The company has a 50 day moving average of $94.95 and a two-hundred day moving average of $99.72. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. LeMaitre Vascular, Inc. has a twelve month low of $78.65 and a twelve month high of $118.01. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 28.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.53.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a return on equity of 15.63% and a net margin of 25.02%.The business had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. During the same period in the previous year, the company posted $0.60 earnings per share. The business’s revenue for the quarter was up 9.6% on a year-over-year basis. As a group, analysts predict that LeMaitre Vascular, Inc. will post 2.89 earnings per share for the current fiscal year.
LeMaitre Vascular Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be issued a $0.25 dividend. This represents a $1.00 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 35.09%.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
See Also
- Five stocks we like better than LeMaitre Vascular
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
